{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:34:30Z","timestamp":1787726070179,"version":"build-2784847793"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007404","name":"Clinical Trial Center, China Medical University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007404","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW109-TDU-B-212-114005"],"award-info":[{"award-number":["MOHW109-TDU-B-212-114005"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CORPG3H0381"],"award-info":[{"award-number":["CORPG3H0381"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.tjog.2021.05.010","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T18:38:42Z","timestamp":1625769522000},"page":"634-638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan"],"prefix":"10.1016","volume":"60","author":[{"given":"Chia-Chen","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Bin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyong-Huey","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Chang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Hsueh","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2021.05.010_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.tjog.2021.05.010_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1055-9965.EPI-16-0520","article-title":"Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992-2013","volume":"26","author":"Noone","year":"2017","journal-title":"Canc Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.tjog.2021.05.010_bib3","series-title":"Cancer registry annual report, 2016 Taiwan","year":"2020"},{"key":"10.1016\/j.tjog.2021.05.010_bib4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3802\/jgo.2013.24.4.342","article-title":"Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan","volume":"24","author":"Chiang","year":"2013","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2017.10.030","article-title":"No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in The Netherlands","volume":"88","author":"Timmermans","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.tjog.2021.05.010_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/CCO.0000000000000110","article-title":"Maintenance therapy in ovarian cancer","volume":"26","author":"Khalique","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib7","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A\u00a0synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2021.05.010_bib9","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib10","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2021.05.010_bib15","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-Ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.tjog.2017.08.026","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer","volume":"56","author":"Liu","year":"2017","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2021.05.010_bib17","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2021.05.010_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian clinical trias incorporating RECIT 1.1 and CA125 agreed by the Gynecologic Cancer InterGroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Canc"},{"issue":"10106","key":"10.1016\/j.tjog.2021.05.010_bib19","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2021.05.010_bib20","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.tjog.2021.05.010_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.tjog.2021.05.010_bib22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s11523-018-0604-z","article-title":"Real-world use and outcomes of olaparib: a population-based cohort study","volume":"13","author":"Eriksson","year":"2018","journal-title":"Targeted Oncol"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455921001224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455921001224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:19:39Z","timestamp":1760897979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455921001224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1028455921001224"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2021.05.010","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2021.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}